Amylyx Pharmaceuticals, Inc. Q2 FY2025 earnings call

Justin Klee highlighted progress across clinical programs, including Avexitide's Phase III LUCIDITY trial for PBH, with recruitment expected to complete by year-end. Camille Bedrosian discussed Avexitide's mechanism and positive trial data from Endo 2025, showing significant reductions in hypoglycemic events. Jim Frates noted a cash position of $180.8 million and discussed operating expenses. Josh Cohen emphasized patient experiences with PBH and the strategic value of antagonizing the GLP-1 pathway.

Amylyx Pharmaceuticals did not break down financial performance by distinct product segments in terms of revenue contribution. Instead, the focus was on progress across clinical programs. The lead asset, Avexitide, is in a pivotal Phase III trial for postbariatric hypoglycemia (PBH), with recruitment expected to complete by year-end. AMX0035 is being studied in progressive supranuclear palsy (PSP) and Wolfram syndrome, with top line data from PSP's Phase IIb trial expected this quarter. AMX0114, an antisense oligonucleotide for ALS, is in a Phase I trial with early cohort data expected by year-end.

Anticipate completing Avexitide's Phase III LUCIDITY trial recruitment by year-end. Expect top line data from PSP's Phase IIb trial this quarter. Early cohort data from AMX0114's LUMINA trial for ALS expected by year-end. Cash runway is expected to last through the end of 2026. Anticipate Avexitide commercial launch in 2027 if approved.

Actual events and results could differ materially from forward-looking statements. Clinical trial recruitment and outcome uncertainties exist.

Q: Seamus Fernandez asked about the market opportunity and enrollment pace in Avexitide's Phase III.

A: Joshua Cohen discussed market learning and progress, noting enrollment expected to complete by year-end.

Q: Michael DiFiore asked about payers and PSP trial duration.

A: Joshua Cohen mentioned lack of clinical evidence for diazoxide/octreotide in PBH; Camille Bedrosian said all PSP trial participants will have completed 24 weeks of treatment.

Q: Corinne Johnson asked about PBH market and surgery trends.

A: Joshua Cohen discussed Roux-en-Y surgery trends and Avexitide's potential across surgeries.

Q: Marc Goodman asked about patient centers and Phase III powering.

A: Joshua Cohen talked about patient locations and Camille Bedrosian discussed conservative powering assumptions for LUCIDITY.